Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Average Rating of “Buy” from Analysts

Inozyme Pharma, Inc. (NASDAQ:INZY) has earned an average rating of “Buy” from the nine research firms that are presently covering the stock, Marketbeat reports. Nine investment analysts have rated the stock with a buy recommendation. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $18.33.

INZY has been the subject of a number of analyst reports. Piper Sandler decreased their target price on shares of Inozyme Pharma from $43.00 to $30.00 and set an “overweight” rating for the company in a research note on Monday, January 13th. Wedbush restated an “outperform” rating and set a $12.00 target price on shares of Inozyme Pharma in a research note on Friday, January 10th. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price target on shares of Inozyme Pharma in a report on Wednesday, November 6th. Raymond James assumed coverage on shares of Inozyme Pharma in a report on Thursday, December 12th. They issued an “outperform” rating and a $26.00 target price on the stock. Finally, HC Wainwright lifted their price target on shares of Inozyme Pharma from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, January 10th.

Inozyme Pharma Price Performance

Shares of NASDAQ INZY opened at $1.38 on Tuesday. Inozyme Pharma has a twelve month low of $1.24 and a twelve month high of $7.80. The company has a quick ratio of 7.68, a current ratio of 7.68 and a debt-to-equity ratio of 0.51. The stock’s 50 day moving average price is $2.36 and its 200-day moving average price is $4.00. The company has a market capitalization of $88.65 million, a PE ratio of -0.88 and a beta of 1.35.

Inozyme Pharma (NASDAQ:INZY) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.05. On average, equities analysts anticipate that Inozyme Pharma will post -1.59 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in INZY. Virtu Financial LLC purchased a new position in Inozyme Pharma in the third quarter worth approximately $64,000. China Universal Asset Management Co. Ltd. purchased a new position in Inozyme Pharma in the fourth quarter worth approximately $38,000. SG Americas Securities LLC purchased a new position in Inozyme Pharma in the third quarter worth approximately $81,000. Cubist Systematic Strategies LLC purchased a new position in Inozyme Pharma in the second quarter worth approximately $84,000. Finally, Readystate Asset Management LP purchased a new position in Inozyme Pharma in the third quarter worth approximately $100,000. Hedge funds and other institutional investors own 88.30% of the company’s stock.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.